reports
- Stephane Foucaud
AUCTUS ON FRIDAY - 08/08/2025
AUCTUS PUBLICATIONS ________________________________________ ADX Energy (ADX AU)C; Target price of A$0.30 per share: High production at Z&G. Low risk exploration drilling in Austria to start in 4Q25/1Q26 – 2Q25 net production of 303 boe/d was higher than our expectations of ~270 boe/d following a 5 well intervention programme at the Zisterdorf and Gaiselberg fields in the Vienna Basin. The programme included (1) repair of subsurface equipment, (2) clean out of a down hole sand control (3) perfor...
EOG EUROPA OIL & GAS (HOLDINGS) PLC
GTE GRAN TIERRA ENERGY
GPRK GEOPARK
EGY VAALCO ENERGY INC.
GENL GENEL ENERGY
ALVOF ALVOPETRO ENERGY LTD
PEN PANORO ENERGY ASA
SNM SHAMARAN PETROLEUM CORP.
VLE VALEURA ENERGY INC.
SQZ SERICA ENERGY
FEC FRONTERA ENERGY CORP
BP. BP P.L.C.
CNE CANACOL ENERGY LTD
KOS KOSMOS ENERGY LTD.
ORC/B ORCA EXPLORATION GROUP CL B
TAL PETROTAL (TAL)
HBR HARBOUR ENERGY PLC
ADX ADX ENERGY LTD
TNZ TENAZ ENERGY CORP
Monthly information on share capital and company voting rights
Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights07/31/2025100,325,22989,428,630 About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology,...
Information mensuelle relative au nombre total des droits de vote et d...
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) NEW YORK, 07 août 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth Code ISIN : FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de vote31/07/2025100 325 22989 428 630 À propos de Cellectis Cellectis est une société de biotechnologie au stade clinique, qui utilise sa technologie pionnière d’édition de génome TALEN® pour développer d...
BP: 1 director
A director at BP bought 45,000 shares at 5.749USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Clo...
- Benoit Valleaux
- Steven Gould
SN. SMITH & NEPHEW PLC
CON CONTINENTAL AKTIENGESELLSCHAFT
INFINEON INFINEON TECHNOLOGIES AG
EBS ERSTE GROUP BANK AG
BEI BEIERSDORF AG
VNA VONOVIA SE
ZAL ZALANDO SE
FRE FRESENIUS SE & CO. KGAA
BAYN BAYER AG
RAA RATIONAL AG
TIT TELECOM ITALIA S.P.A.
AD KONINKLIJKE AHOLD DELHAIZE N.V.
BP. BP P.L.C.
CCEP COCA-COLA EUROPEAN PARTNERS PLC
ENR SIEMENS ENERGY AG
NOVO B NOVO NORDISK A/S
QGEN QIAGEN N.V.
- Benoit Valleaux
- Steven Gould
SN. SMITH & NEPHEW PLC
CON CONTINENTAL AKTIENGESELLSCHAFT
INFINEON INFINEON TECHNOLOGIES AG
EBS ERSTE GROUP BANK AG
BEI BEIERSDORF AG
VNA VONOVIA SE
ZAL ZALANDO SE
FRE FRESENIUS SE & CO. KGAA
BAYN BAYER AG
RAA RATIONAL AG
TIT TELECOM ITALIA S.P.A.
AD KONINKLIJKE AHOLD DELHAIZE N.V.
BP. BP P.L.C.
CCEP COCA-COLA EUROPEAN PARTNERS PLC
ENR SIEMENS ENERGY AG
NOVO B NOVO NORDISK A/S
QGEN QIAGEN N.V.
- Ahmed Ben Salem
- Ahmed Ben Salem
ENI S.p.A.: 1 director
A director at ENI S.p.A. sold 4,679 shares at 14.744EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
- Ahmed Ben Salem
- Baptiste Lebacq
ETL EUTELSAT COMMUNICATIONS SA
SCR SCOR SE
OERL OC OERLIKON CORPORATION AG
ALCLS CELLECTIS SA
BOSS HUGO BOSS AG
NOEJ NORMA GROUP SE
ERA ERAMET SA
LNZ LENZING AG
NDA AURUBIS AG
KRN KRONES AG
COFA COFACE SA
TRP TERAPLAST
MAU ETABLISSEMENTS MAUREL & PROM SA
SFQ SAF-HOLLAND SE
ADTN ADTRAN HOLDINGS INC
STM STABILUS SE
- Martin Marandon-Carlhian
- Stephane Houri
DHL DHL GROUP
INFINEON INFINEON TECHNOLOGIES AG
FME FRESENIUS MEDICAL CARE AG
DGE DIAGEO PLC
RI PERNOD RICARD SA
RCO REMY COINTREAU SA
ADEN ADECCO GROUP AG
CEZ CEZ AS
RAA RATIONAL AG
OTP OTP BANK NYRT
ABI ANHEUSER-BUSCH INBEV SA/NV
BP. BP P.L.C.
BNTX BIONTECH SE
CPR DAVIDE CAMPARI-MILANO N.V.
- Ahmed Ben Salem
- Baptiste Lebacq
ETL EUTELSAT COMMUNICATIONS SA
SCR SCOR SE
OERL OC OERLIKON CORPORATION AG
ALCLS CELLECTIS SA
BOSS HUGO BOSS AG
NOEJ NORMA GROUP SE
ERA ERAMET SA
LNZ LENZING AG
NDA AURUBIS AG
KRN KRONES AG
COFA COFACE SA
TRP TERAPLAST
MAU ETABLISSEMENTS MAUREL & PROM SA
SFQ SAF-HOLLAND SE
ADTN ADTRAN HOLDINGS INC
STM STABILUS SE
- Martin Marandon-Carlhian
- Stephane Houri
DHL DHL GROUP
INFINEON INFINEON TECHNOLOGIES AG
FME FRESENIUS MEDICAL CARE AG
DGE DIAGEO PLC
RI PERNOD RICARD SA
RCO REMY COINTREAU SA
ADEN ADECCO GROUP AG
CEZ CEZ AS
RAA RATIONAL AG
OTP OTP BANK NYRT
ABI ANHEUSER-BUSCH INBEV SA/NV
BP. BP P.L.C.
BNTX BIONTECH SE
CPR DAVIDE CAMPARI-MILANO N.V.
- Ahmed Ben Salem
- Ahmed Ben Salem
- Martial Descoutures
- Oussema Denguir
- Martial Descoutures
- Oussema Denguir
Cellectis Reports Second Quarter 2025 Financial Results & Business Upd...
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates Cellectis to host an Investor R&D Day in New York City on October 16, 2025: Phase 1 dataset and late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL to be presented End-of-Phase 1 meetings with FDA & EMA for lasme-cel (UCART22) in r/r B-ALL completed in July 2025; on track to launch pivotal Phase 2 in H2 2025 Servier arbitration: arbitral decision expected to be rendered on or before December 15, 2025 eti-cel (UCART20x22): Phase 1 study in r/r NHL ongoing with readout expected in late 2025 AstraZene...
Cellectis publie ses résultats financiers du deuxième trimestre 2025 e...
Cellectis publie ses résultats financiers du deuxième trimestre 2025 et une mise à jour de ses activités Cellectis organise un R&D Day dédié aux investisseurs à New York le 16 octobre 2025 : les données de phase 1 et la stratégie de développement de lasmé-cel (UCART22) dans la LAL-B r/r y seront présentés Les réunions de fin de phase 1 avec la FDA et l’EMA concernant lasmé-cel (UCART22) dans la LAL-B r/r ont eu lieu en juillet 2025 ; le lancement de la phase 2 pivotale est prévu pour le second semestre 2025 Arbitrage Servier : la décision arbitrale devrait être rendue le 15 décembre 2025, o...
Cellectis to Report Second Quarter 2025 Financial Results on August 4,...
Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025 NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2025 ending June 30, 2025 on Monday August 4, 2025 after the close of the US market. The publication will be followed by an investor conference call and webcast on Tuesday August 5, 2025 at 8:00 AM ET ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.